Burkert M, Blanc E, Thiessen N, Weber C, Toedling J, Monti R
iScience. 2024; 27(10):110918.
PMID: 39635126
PMC: 11615189.
DOI: 10.1016/j.isci.2024.110918.
Zhang Y, Remillard D, Onubogu U, Karakyriakou B, Asiaban J, Ramos A
Nat Struct Mol Biol. 2023; 30(8):1160-1171.
PMID: 37488358
PMC: 10529074.
DOI: 10.1038/s41594-023-01041-4.
Kim E, Lee B, Lee J, Sung K, Kim J
Diagnostics (Basel). 2021; 11(9).
PMID: 34574043
PMC: 8465051.
DOI: 10.3390/diagnostics11091702.
Prajapati B, Fatma M, Fatima M, Khan M, Sinha S, Seth P
Front Mol Neurosci. 2020; 12:293.
PMID: 31920530
PMC: 6920248.
DOI: 10.3389/fnmol.2019.00293.
Smith C, Catchpoole D, Hutvagner G
Front Genet. 2019; 10:798.
PMID: 31616462
PMC: 6764412.
DOI: 10.3389/fgene.2019.00798.
Opportunities and challenges of circulating biomarkers in neuroblastoma.
Trigg R, Shaw J, Turner S
Open Biol. 2019; 9(5):190056.
PMID: 31088252
PMC: 6544987.
DOI: 10.1098/rsob.190056.
Identification and characterization of the lncRNA signature associated with overall survival in patients with neuroblastoma.
Yerukala Sathipati S, Sahu D, Huang H, Lin Y, Ho S
Sci Rep. 2019; 9(1):5125.
PMID: 30914706
PMC: 6435792.
DOI: 10.1038/s41598-019-41553-y.
Non-High-Risk Neuroblastoma: Classification and Achievements in Therapy.
Meany H
Children (Basel). 2019; 6(1).
PMID: 30626019
PMC: 6352142.
DOI: 10.3390/children6010005.
Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas.
Naraparaju K, Kolla V, Zhuang T, Higashi M, Iyer R, Kolla S
Oncotarget. 2016; 7(13):15977-85.
PMID: 26895110
PMC: 4941291.
DOI: 10.18632/oncotarget.7434.
Long noncoding RNAs and neuroblastoma.
Pandey G, Kanduri C
Oncotarget. 2015; 6(21):18265-75.
PMID: 26087192
PMC: 4621889.
DOI: 10.18632/oncotarget.4251.
The tumour suppressor CHD5 forms a NuRD-type chromatin remodelling complex.
Kolla V, Naraparaju K, Zhuang T, Higashi M, Kolla S, Blobel G
Biochem J. 2015; 468(2):345-52.
PMID: 25825869
PMC: 4487910.
DOI: 10.1042/BJ20150030.
Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells.
Ren X, Bai X, Zhang X, Li Z, Tang L, Zhao X
Mol Cell Proteomics. 2014; 14(2):316-28.
PMID: 25505154
PMC: 4350028.
DOI: 10.1074/mcp.M114.041905.
Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses.
Abbasi M, Rifatbegovic F, Brunner C, Ladenstein R, Ambros I, Ambros P
Mol Oncol. 2014; 9(3):545-54.
PMID: 25467309
PMC: 5528711.
DOI: 10.1016/j.molonc.2014.10.010.
Role of CHD5 in human cancers: 10 years later.
Kolla V, Zhuang T, Higashi M, Naraparaju K, Brodeur G
Cancer Res. 2014; 74(3):652-8.
PMID: 24419087
PMC: 3965582.
DOI: 10.1158/0008-5472.CAN-13-3056.
Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction.
Bronicki L, Jasmin B
RNA. 2013; 19(8):1019-37.
PMID: 23861535
PMC: 3708524.
DOI: 10.1261/rna.039164.113.
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
Schleiermacher G, Mosseri V, London W, Maris J, Brodeur G, Attiyeh E
Br J Cancer. 2012; 107(8):1418-22.
PMID: 22976801
PMC: 3494425.
DOI: 10.1038/bjc.2012.375.
Mechanisms of CHD5 Inactivation in neuroblastomas.
Koyama H, Zhuang T, Light J, Kolla V, Higashi M, McGrady P
Clin Cancer Res. 2012; 18(6):1588-97.
PMID: 22294723
PMC: 3306487.
DOI: 10.1158/1078-0432.CCR-11-2644.
Neuroblastoma: issues in transplantation.
Grupp S, Asgharzadeh S, Yanik G
Biol Blood Marrow Transplant. 2012; 18(1 Suppl):S92-100.
PMID: 22226119
PMC: 3260463.
DOI: 10.1016/j.bbmt.2011.10.020.
Knowing your ABCCs: novel functions of ABCC transporters.
Brodeur G
J Natl Cancer Inst. 2011; 103(16):1207-8.
PMID: 21799181
PMC: 3156804.
DOI: 10.1093/jnci/djr277.
Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.
Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A
N Engl J Med. 2010; 363(14):1313-23.
PMID: 20879880
PMC: 2993160.
DOI: 10.1056/NEJMoa1001527.